Bronchiolitis

Not to be confused with bronchitis, Obliterative bronchiolitis, or bronchiolitis obliterans organizing pneumonia.

Bronchiolitis
Depiction of the location of bronchiolitis in the lungs and viral shedding.
Specialty	Emergency medicine, pediatrics
Symptoms	Fever, cough, runny nose, wheezing, breathing problems [1]
Complications	Shortness of breath, dehydration [1]
Usual onset	Less than 2 years old [2]
Causes	Viral disease (respiratory syncytial virus, human rhinovirus) [2]
Diagnostic method	Based on symptoms [1]
Differential diagnosis	Asthma, pneumonia, heart failure, allergic reaction, cystic fibrosis [1]
Treatment	Symptomatic treatment (oxygen, support with feeding, intravenous fluids) [3]
Frequency	~20% (children less than 2) [2] [1]
Deaths	1% (among those hospitalized) [4]

Bronchiolitis is inflammation of the small airways also known as the bronchioles in the lungs. Acute bronchiolitis is caused by a viral infection, usually affecting children younger than two years of age. ^[5] Symptoms may include fever, cough, runny nose or rhinorrhea, and wheezing. ^[1] More severe cases may be associated with nasal flaring, grunting, or respiratory distress. ^[1] If the child has not been able to feed properly due to the illness, signs of dehydration may be present. ^[1]

Chronic bronchiolitis is more common in adults and has various causes, one of which is bronchiolitis obliterans. ^{[5] [6]} Often when people refer to bronchiolitis, they are referring to acute bronchiolitis in children. ^[5]

Acute bronchiolitis is usually the result of viral infection by respiratory syncytial virus (RSV) (59.2% of cases) or human rhinovirus (19.3% of cases). ^[7] Diagnosis is generally based on symptoms. ^[1] Tests such as a chest X-ray or viral testing are not routinely needed, but may be used to rule out other diseases. ^[2]

There is no specific medicine that is used to treat bronchiolitis. ^{[3] [8]} Symptomatic treatment at home is generally effective and most children do not require hospitalization. ^[1] This can include antipyretics such as acetaminophen for fever and nasal suction for nasal congestion, both of which can be purchased over the counter. ^[1] Occasionally, hospital admission for oxygen, particularly high flow nasal cannula, or intravenous fluids is needed in more severe cases of disease. ^[1]

Video explanation

About 10% to 30% of children under the age of two years are affected by bronchiolitis at some point in time. ^{[1] [2]} It commonly occurs in the winter season in the Northern Hemisphere. ^[1] It is the leading cause of hospitalizations in those less than one year of age in the United States. ^{[9] [8]} The risk of death among those who are admitted to hospital is extremely low at about 1%. ^[4] Outbreaks of the condition were first described in the 1940s. ^[10]

Signs and symptoms

Bronchiolitis typically presents in children under two years old and is characterized by symptoms of a respiratory illness. ^[1]

Signs of the disease include: ^[9]

• fever
• rhinorrhea
• cough
• wheeze
• mild tachypnea or increased breathing

Some signs of severe disease include: ^[11]

• increased work of breathing (such as use of accessory muscles of respiration, rib & sternal retraction, tracheal tug)
• severe chest wall recession (Hoover's sign)
• presence of nasal flaring and/or grunting
• severe tachypnea or increased breathing
• hypoxia (low oxygen levels)
• cyanosis (bluish skin)
• lethargy and decreased activity
• poor feeding (less than half of usual fluid intake in preceding 24 hours)

These symptoms can develop over one to three days. ^[1] Crackles or wheeze are typical findings on listening to the chest with a stethoscope. Wheezes can occasionally be heard without a stethoscope. The child may also experience apnea, or brief pauses in breathing, but this can occur due to many conditions that are not just bronchiolitis. After the acute illness, it is common for the airways to remain sensitive for several weeks, leading to recurrent cough and wheeze. ^[1]

Causes

Bronchiolitis is most commonly caused by respiratory syncytial virus ^[7] (RSV, also known as human pneumovirus). Other agents that cause this illness include, but are not limited to, human metapneumovirus, influenza, parainfluenza, coronavirus, adenovirus, rhinovirus and mycoplasma. ^{[12] [13]}

RSV, which is the most common cause of acute bronchiolitis in children.

Risk factors

Children are at an increased risk for progression to severe respiratory disease if they have any of the following additional risk factors: ^{[8] [9] [13] [14]}

• Preterm infant (gestational age less than 37 weeks)
• Younger age at onset of illness (less than 3 months of age)
• Congenital heart disease
• Immunodeficiency
• Chronic lung disease
• Neurological disorders
• Tobacco smoke exposure

Diagnosis

The diagnosis is typically made by a provider through clinical history and physical exam. Chest X-ray is sometimes useful to exclude bacterial pneumonia, but not indicated in routine cases. ^[1] Chest x-ray may also be useful in people with impending respiratory failure. ^[15] Additional testing such as blood cultures, complete blood count, and electrolyte analyses are not recommended for routine use although may be useful in children with multiple comorbidities or signs of sepsis or pneumonia. ^{[8] [15]} Electrolyte analyses may be performed if there is concern for dehydration. ^[1]

An X-ray of a child with RSV showing the typical bilateral perihilar fullness of bronchiolitis. The arrows are pointing to the portion of the X-ray that is abnormal and shows fluffy perihilar fullness.

Testing for the specific viral cause can be done but has little effect on management and thus is not routinely recommended. ^[16] The COVID pandemic has led to more viral testing to exclude COVID as a cause of the infection. At that point providers often also add on a flu and RSV test for completeness. ^[17] RSV testing by direct immunofluorescence testing of a swab of the nose had a sensitivity of 61% and specificity of 89%, so it is not alway accurate. ^{[13] [15]} Identification of those who are RSV-positive can help providers recommend isolation precautions in the hospital or at home to avoid the infection spreading to others. ^[8] Identification of the virus may help reduce the use of antibiotics because antibiotics are not recommended for viral illnesses such as bronchiolitis. ^[15]

It is extremely rare for infants to be co-infected with a bacterial illness while having bronchiolitis. Infants with bronchiolitis between the age of two and three months have a second infection by bacteria (usually a urinary tract infection) less than 6% of the time. ^[18] When further evaluated with a urinalysis, infants with bronchiolitis had a accompanying UTI 0.8% of the time. ^[19]

Differential diagnosis

There are many childhood illnesses that can present with respiratory symptoms, particularly persistent cough, runny nose, and wheezing. ^{[9] [20]} Bronchiolitis may be differentiated from some of these by the characteristic pattern of preceding febrile upper respiratory tract symptoms lasting for 1 to 3 days with associated persistent cough, increased work of breathing, and wheezing. ^[20] However, some infants may present without fever (30% of cases) or may present with apnea without other signs or with poor weight gain prior to onset of symptoms. ^[20] In such cases, additional laboratory testing and radiographic imaging may be useful. ^{[9] [20]} The following are some other diagnoses to consider in an infant presenting with signs of bronchiolitis: ^[1]

• Upper Respiratory Infection
• Asthma and reactive airway disease
• Bacterial pneumonia
• Whooping cough
• Foreign body aspiration
• Congenital heart disease
• Allergic reaction
• Vascular ring
• Heart failure
• Cystic fibrosis
• Chronic pulmonary disease

Prevention

Prevention of bronchiolitis relies strongly on measures to reduce the spread of the viruses that cause respiratory infections (that is, handwashing, and avoiding exposure to those symptomatic with respiratory infections). ^{[8] [9]} Guidelines are mixed on the use of gloves, aprons, or personal protective equipment. ^[8]

Handwashing can help reduce the spread of bronchiolitis.

One way to improve the immune system is to feed the infant with breast milk, especially during the first month of life. ^{[14] [21]} Respiratory infections were shown to be significantly less common among breastfed infants and fully breastfed RSV-positive hospitalized infants had shorter hospital stays than non or partially breastfed infants. ^[9] Guidelines recommend exclusive breastfeeding for infants for the first 6 months of life to avoid infection with bronchiolitis. ^[9]

The US Food and Drug Administration (FDA) has currently approved two RSV vaccines for adults ages 60 and older, Arexvy (GSK plc) and Abrysvo (Pfizer). ^[22] Abrysvo is also approved for "immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age." ^[23] It is unclear how effective these vaccines will be in preventing infection with bronchiolitis since they are new, although the FDA has approved them due to the clear benefit that they have shown in clinical trials. ^[23]

Nirsevimab, a monoclonal antibody against RSV, is approved by the FDA for all children younger than 8 months in their first RSV season. ^[22] Additionally, children aged 8 to 19 months who are at increased risk may be recommended to receive Nirsevimab as they enter their second RSV season if they have increased risk factors for infection with RSV. ^{[24] [25]}

A second monoclonal antibody, Palivizumab, can be administered to prevent bronchiolitis to infants less than one year of age that were born prematurely and that have underlying heart disease or chronic lung disease of prematurity. ^[9] Otherwise healthy premature infants that were born after a gestational age of 29 weeks should not be administered Palivizumab, as the harms outweigh the benefits. ^[9]

Tobacco smoke exposure has been shown to increase both the rates of lower respiratory disease in infants, as well as the risk and severity of bronchiolitis. ^[9] Tobacco smoke lingers in the environment for prolonged periods and on clothing even when smoking outside the home. ^[9] Guidelines recommend that parents be fully educated on the risks of tobacco smoke exposure on children with bronchiolitis. ^{[9] [20]}

Management

Treatment of bronchiolitis is usually focused on the hydration and symptoms instead of the infection itself since the infection will run its course. Complications of bronchiolitis are typically from the symptoms themselves. ^[26] Without active treatment, cases resolved in approximately eight to fifteen days. ^[27] Children with severe symptoms, especially poor feeding or dehydration, may be considered for hospital admission. ^[8] Oxygen saturation under 90%-92% as measured with pulse oximetry is also frequently used as an indicator of need for hospitalization. ^[8] High-risk infants, apnea, cyanosis, malnutrition, and diagnostic uncertainty are additional indications for hospitalization. ^[8]

Most guidelines recommend sufficient fluids and nutritional support for affected children along with frequent nasal suctioning. ^[8] Measures for which the recommendations were mixed include nebulized hypertonic saline, nebulized epinephrine, and chest physiotherapy. ^{[1] [8] [28] [29] [30]} Treatments which the evidence does not support include salbutamol, steroids, antibiotics, antivirals, and heliox. ^{[1] [31] [32] [33]}

Outpatient Management

Nutrition

Maintaining hydration is an important part of management of bronchiolitis. ^{[9] [15] [34]} Infants with mild pulmonary symptoms may require only observation if feeding is unaffected. ^[9] However, oral intake may be affected by nasal secretions and increased work of breathing. ^[9] Poor feeding or dehydration, defined as less than 50% of usual intake, is often cited as an indication for hospital admission. ^[8]

Breathing/ Oxygen

Children must be closely monitored for changes in ability to breathe. Nasal suction can be used at home in order to decrease nasal congestion and open the airways. ^[1]

Inadequate oxygen supply to the tissue is one of the main concerns during severe bronchiolitis and oxygen saturation is often closely associated with both the need for hospitalization and continued length of hospital stay in children with bronchiolitis. ^[15] However, oxygen saturation is a poor predictor of respiratory distress. ^[9] Accuracy of pulse oximetry is limited in the 76% to 90% range and there is weak correlation between oxygen saturation and respiratory distress as brief hypoxemia is common in healthy infants. ^{[9] [15]} Additionally, pulse oximetry is associated with frequent false alarms and parental stress and fatigue. ^[9]

Nasal Suction

Infants are nose breathers and bronchiolitis causes congestion of the airways with secretions that can make it difficult to feed and breathe. ^[35] Nasal suctioning is a very common supportive measure used at home to decrease nasal congestion. ^[36] It has not been extensively studied in the literature, but can be used to decrease secretions in the nose and has been proven mildly effective in one experimental trial. ^[36] A nasal suction bulb can be purchased over the counter and directions for its use can be explained by a provider or on the back of the box. Clinical guidelines state that routine suctioning is safe and can provide relief for infants which allows them to eat and sleep more comfortably. ^[9]

In those same clinical guidelines, it is stated that deep suctioning, which is often performed in the hospital is not recommended as it may lead to increased length of hospital stay in children with bronchiolitis. ^[9]

Inpatient/ Hospital Management

Nutrition/ Fluid Therapy

When children are experiencing poor feeding or dehydration, the child may be admitted to the hospital. ^{[9] [20] [15]} Approximately 50% of infants who are hospitalized due to bronchiolitis require fluid therapy. ^[37] There are two main approaches to fluid therapy: intravenous (IV) fluid therapy and enteral tube fluid therapy (nasogastric or orogastric). ^[37] Both approaches to fluid therapy are associated with a similar length of hospital stay. ^[37] Enteral tube fluid therapy may reduce the risk of local complications, but the evidence for or against each approach is not clear. ^[37] The risk of health care caused hyponatremia and fluid retention are minimal with the use of isotonic fluids such as normal saline. ^[9]

Oxygen

Nasal cannula

If children are having trouble maintaining their oxygen saturations on room air, clinicians may choose to give additional oxygen to children with bronchiolitis if their oxygen saturation is below 90%. ^{[9] [20] [15]} Additionally, clinicians may choose to use continuous pulse oximetry in these people to monitor them. ^[9]

The use of humidified, heated, high-flow nasal cannula may be a safe initial therapy to decrease work of breathing and need for intubation. ^{[9] [38] [39]} High flow nasal cannula may still be used in severe cases prior to intubation. ^{[20] [40] [41] [ needs update ]} CPAP does not have clear evidence of benefit. ^[42]

Blood gas testing is not routinely recommended for people hospitalized with the disease. ^{[15] [20]} However, people with severe worsening respiratory distress or impending respiratory failure may be considered for capillary blood gas testing. ^[20]

Contradicting Evidence

Hypertonic saline

Guidelines recommend against the use of nebulized hypertonic saline in the emergency department for children with bronchiolitis but it may be given to children who are hospitalized. ^{[9] [15]}

Nebulized hypertonic saline (3%) has limited evidence of benefit and previous studies lack consistency and standardization. ^{[43] [44] [45]} It does not reduce the rate of hospitalization when therapy is given in the emergency department or outpatient setting. ^[9] A 2017 review found tentative evidence that it reduces the risk of hospitalization, duration of hospital stay, and improved the severity of symptoms. ^{[43] [46]} Side effects were mild and resolved spontaneously. ^[43]

Bronchodilators

Guidelines recommend against the use of bronchodilators in children with bronchiolitis as evidence does not support a change in outcomes with such use. ^{[9] [20] [47] [48]} Additionally, there are adverse effects to the use of bronchodilators in children such as tachycardia and tremors, as well as adding increased cost to the medical visit. ^{[49] [47]}

Several studies have shown that bronchodilation with β-adrenergic agents such as salbutamol may improve symptoms briefly but do not affect the overall course of the illness or reduce the need for hospitalization. ^[9]

However, there are conflicting recommendations about the use of a trial of a bronchodilator, especially in those with history of previous wheezing. ^{[8] [9] [15]} Bronchiolitis-associated wheezing is likely not effectively alleviated by bronchodilators anyway as it is caused by airway obstruction and plugging of the small airway diameters by luminal debris, not bronchospasm as in asthma-associated wheezing that bronchodilators usually treat well. ^[47] If a clinician is concerned that reactive airway disease or asthma may be a component of the illness, a bronchodilator may be administered. ^[9]

Anticholinergic inhalers, such as ipratropium bromide, have a modest short-term effect at best and are not recommended for treatment. ^{[20] [50] [51]}

Epinephrine

The current state of evidence suggests that nebulized epinephrine is not indicated for children with bronchiolitis except as a trial of rescue therapy for severe cases. ^{[9] [20]}

Epinephrine is an α and β adrenergic agonist that is used to treat other upper respiratory tract illnesses, such as croup, as a nebulized solution. ^[52] Current guidelines do not support the outpatient use of epinephrine in bronchiolitis given the lack of substantial sustained benefit. ^[9]

A 2017 review found inhaled epinephrine with corticosteroids did not change the need for hospitalization or the time spent in hospital. ^[53] Other studies suggest a synergistic effect of epinephrine with corticosteroids but have not consistently demonstrated benefits in clinical trials. ^[9] Guidelines recommend against its use currently. ^{[9] [8]}

Non-effective Treatments

• Ribavirin is an antiviral drug which does not appear to be effective for bronchiolitis. ^[12]
• Antibiotics are often given in case of a bacterial infection complicating bronchiolitis, but have no effect on the underlying viral infection and their benefit is not clear. ^{[12] [54] [55]} The risks of bronchiolitis with a concomitant serious bacterial infection among hospitalized febrile infants is minimal and work-up and antibiotics are not justified. ^{[9] [19]} Azithromycin adjuvant therapy may reduce the duration of wheezing and coughing in children with bronchiolitis but has not effect on length of hospital stay or duration of oxygen therapy. ^[56]
• Corticosteroids, although useful in other respiratory disease such as asthma and croup, have no proven benefit in bronchiolitis treatment and are not advised. ^{[9] [8] [12] [57] [58]} Additionally, corticosteroid therapy in children with bronchiolitis may prolong viral shedding and transmissibility. ^[9] The overall safety of corticosteroids is questionable. ^[59]
• Leukotriene inhibitors, such as montelukast, have not been found to be beneficial and may increase adverse effects. ^{[8] [60] [61] [62]}
• Immunoglobulins are of unclear benefit. ^[63]

Experimental Trials

Currently other medications do not yet have evidence to support their use, although they have been studied for use in bronchiolitis. ^{[9] [64]} Experimental trials with novel antiviral medications in adults are promising but it remains unclear if the same benefit will be present. ^[15]

• Surfactant had favorable effects for severely critical infants on duration of mechanical ventilation and ICU stay however studies were few and small. ^{[65] [12]}
• Chest physiotherapy, such as vibration or percussion, to promote airway clearance may slightly reduce duration of oxygen therapy but there is a lack of evidence that demonstrates any other benefits. ^{[9] [66] [67]} People with difficulty clearing secretions due to underlying disorders such as spinal muscle atrophy or severe tracheomalacia may be considered for chest physiotherapy. ^[20]
• Heliox, a mixture of oxygen and the inert gas helium, may be beneficial in infants with severe acute RSV bronchiolitis who require CPAP but overall evidence is lacking. ^{[28] [68]}
• DNAse has not been found to be effective but might play a role in severe bronchiolitis complicated by atelectasis. ^[69]
• There are no systematic reviews or controlled trials on the effectiveness of nasal decongestants, such as xylometazoline, for the treatment of bronchiolitits. ^[12]
• Overall evidence is insufficient to support the use of alternative medicine. ^[70] There is tentative evidence for Chinese herbal medicine, vitamin D, N-acetylcysteine, and magnesium but this is insufficient to recommend their use. ^[70]

Epidemiology

Histology Slide - Acute inflammatory exudate occluding the lumen of the bronchiole and acute inflammation of part of the wall of the bronchiole. It shows at the cellular level the inflammation that occurs in the bronchiole of a child with bronchiolitis.

Bronchiolitis typically affects infants and children younger than two years, principally during the autumn and winter. ^[15] It is the leading cause of hospital admission for respiratory disease among infants in the United States and accounts for one out of every 13 primary care visits. ^[8] Bronchiolitis accounts for 3% of emergency department visits for children under 2 years old. ^[12] Bronchiolitis is the most frequent lower respiratory tract infection and hospitalization in infants worldwide. ^[15]

COVID-19 Pandemic

The COVID-19 pandemic rapidly changed the transmission and presentation starting in late 2019. ^[17] During the pandemic, there was a sharp decrease in cases of bronchiolitis and other respiratory illness, which is likely due to social distancing and other precautions. ^[17] After social distancing and other precautions were lifted, there was increases in the cases of RSV and bronchiolitis worldwide to varying degrees. ^[17] There is unclear evidence on how COVID-19 will affect bronchiolitis moving forward. Recent evidence suggests that bronchiolitis still poses a large disease burden to both primary care providers and emergency departments. ^[71]

References

1. Friedman JN, Rieder MJ, Walton JM (November 2014). "Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age". Paediatrics & Child Health. 19 (9): 485–498. doi:10.1093/pch/19.9.485. PMC   4235450 . PMID   25414585.
2. Schroeder AR, Mansbach JM (June 2014). "Recent evidence on the management of bronchiolitis". Current Opinion in Pediatrics. 26 (3): 328–333. doi:10.1097/MOP.0000000000000090. PMC   4552182 . PMID   24739493.
3. Hancock DG, Charles-Britton B, Dixon DL, Forsyth KD (September 2017). "The heterogeneity of viral bronchiolitis: A lack of universal consensus definitions". Pediatric Pulmonology. 52 (9): 1234–1240. doi:10.1002/ppul.23750. PMID   28672069. S2CID   3454691.
4. Ali A, Plint AC, Klassen TP (2012). "Bronchiolitis". In Kendig EL, Wilmott RW, Boat TF, Bush A, Chernick V (eds.). Kendig and Chernick's Disorders of the Respiratory Tract in Children. Elsevier Health Sciences. p. 450. ISBN   978-1437719840.
5. Ryu JH, Azadeh N, Samhouri B, Yi E (2020). "Recent advances in the understanding of bronchiolitis in adults". F1000Research. 9: 568. doi: 10.12688/f1000research.21778.1 . PMC   7281671 . PMID   32551095.
6. Kumar V, Abbas AK, Aster JC (2018). Robbins basic pathology (Tenth ed.). Philadelphia, Pennsylvania: Elsevier. p. 502. ISBN   9780323353175.
7. Kenmoe, Sebastien; Kengne-Nde, Cyprien; Ebogo-Belobo, Jean Thierry; Mbaga, Donatien Serge; Fatawou Modiyinji, Abdou; Njouom, Richard (12 November 2020). de Swart, Rik L. (ed.). "Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19 pandemic era". PLOS ONE. 15 (11): e0242302. doi: 10.1371/journal.pone.0242302 . ISSN   1932-6203. PMC   7660462 . PMID   33180855.
8. Kirolos A, Manti S, Blacow R, Tse G, Wilson T, Lister M, et al. (October 2020). "A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis". The Journal of Infectious Diseases. 222 (Suppl 7): S672–S679. doi: 10.1093/infdis/jiz240 . hdl: 20.500.11820/7d4708e3-7cdc-49f7-a9b3-a29040f4ff4e . PMID   31541233.
9. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. (November 2014). "Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis". Pediatrics. 134 (5): e1474–e1502. doi: 10.1542/peds.2014-2742 . PMID   25349312.
10. Graham BS, Anderson LJ (2013). Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology. Vol. 372. Springer Science & Business Media. pp. 391–404. doi:10.1007/978-3-642-38919-1_20. ISBN   9783642389191. PMC   7121045 . PMID   24362701.
11. BRONCHIOLITIS IN CHILDREN (Sign Guideline 91). Scottish Intercollegiate Guidelines Network. 2006. ISBN   9781905813018. Archived from the original on 1 November 2012. Retrieved 6 December 2012.
12. Bourke T, Shields M (April 2011). "Bronchiolitis". BMJ Clinical Evidence. 2011. PMC   3275170 . PMID   21486501.
13. Bordley WC, Viswanathan M, King VJ, Sutton SF, Jackman AM, Sterling L, Lohr KN (February 2004). "Diagnosis and testing in bronchiolitis: a systematic review". Archives of Pediatrics & Adolescent Medicine. 158 (2): 119–126. doi: 10.1001/archpedi.158.2.119 . PMID   14757603.
14. Carbonell-Estrany X, Figueras-Aloy J, Law BJ (November 2004). "Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings". The Pediatric Infectious Disease Journal. 23 (11 Suppl): S193–S201. doi: 10.1097/01.inf.0000144664.31888.53 . PMID   15577573. S2CID   39990266.
15. Caballero MT, Polack FP, Stein RT (1 November 2017). "Viral bronchiolitis in young infants: new perspectives for management and treatment". Jornal de Pediatria. 93 (Suppl 1): 75–83. doi: 10.1016/j.jped.2017.07.003 . PMID   28859915.
16. Zorc JJ, Hall CB (February 2010). "Bronchiolitis: recent evidence on diagnosis and management". Pediatrics. 125 (2): 342–349. doi:10.1542/peds.2009-2092. PMID   20100768. S2CID   4932917.
17. Sabeena, Sasidharanpillai; Ravishankar, Nagaraja; Robin, Sudandiradas; Pillai, SabithaSasidharan (2023). "The impact of coronavirus disease 2019 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus: A systematic review and meta-analysis". Indian Journal of Public Health. 67 (2): 284–291. doi: 10.4103/ijph.ijph_1334_22 . ISSN   0019-557X. PMID   37459026.
18. Ralston S, Hill V, Waters A (October 2011). "Occult serious bacterial infection in infants younger than 60 to 90 days with bronchiolitis: a systematic review". Archives of Pediatrics & Adolescent Medicine. 165 (10): 951–956. doi: 10.1001/archpediatrics.2011.155 . PMID   21969396.
19. McDaniel CE, Ralston S, Lucas B, Schroeder AR (March 2019). "Association of Diagnostic Criteria With Urinary Tract Infection Prevalence in Bronchiolitis: A Systematic Review and Meta-analysis". JAMA Pediatrics. 173 (3): 269–277. doi:10.1001/jamapediatrics.2018.5091. PMC   6439888 . PMID   30688987.
20. "1 Recommendations | Bronchiolitis in children: diagnosis and management | Guidance | NICE". www.nice.org.uk. June 2015. Retrieved 31 October 2019.
21. Belderbos ME, Houben ML, van Bleek GM, Schuijff L, van Uden NO, Bloemen-Carlier EM, et al. (February 2012). "Breastfeeding modulates neonatal innate immune responses: a prospective birth cohort study". Pediatric Allergy and Immunology. 23 (1): 65–74. doi:10.1111/j.1399-3038.2011.01230.x. PMID   22103307. S2CID   7605378.
22. "Respiratory Syncytial Virus (RSV)". U.S. Food & Drug Administration. 14 September 2023. Retrieved 27 October 2023.
23. "ABRYSVO". U.S. Food & Drug Administration. Retrieved 27 October 2023.
24. "FDA Approves New Drug to Prevent RSV in Babies and Toddlers". U.S. Food & Drug Administration. 17 July 2023. Retrieved 27 October 2023.
25. "RSV Immunization for Children 19 months and Younger". Centers for Disease Control and Prevention. Retrieved 27 October 2023.
26. Wright M, Mullett CJ, Piedimonte G (October 2008). "Pharmacological management of acute bronchiolitis". Therapeutics and Clinical Risk Management. 4 (5): 895–903. doi: 10.2147/tcrm.s1556 . PMC   2621418 . PMID   19209271.
27. Thompson M, Vodicka TA, Blair PS, Buckley DI, Heneghan C, Hay AD (December 2013). "Duration of symptoms of respiratory tract infections in children: systematic review". BMJ. 347: f7027. doi:10.1136/bmj.f7027. PMC   3898587 . PMID   24335668.
28. Liet JM, Ducruet T, Gupta V, Cambonie G (September 2015). "Heliox inhalation therapy for bronchiolitis in infants". The Cochrane Database of Systematic Reviews. 2015 (9): CD006915. doi:10.1002/14651858.CD006915.pub3. PMC   8504435 . PMID   26384333.
29. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al. (June 2011). "Epinephrine for bronchiolitis". The Cochrane Database of Systematic Reviews (6): CD003123. doi:10.1002/14651858.CD003123.pub3. PMID   21678340.
30. Roqué-Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C, Vilaró J (April 2023). "Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old". The Cochrane Database of Systematic Reviews. 2023 (4): CD004873. doi:10.1002/14651858.CD004873.pub6. PMC   10070603 . PMID   37010196.
31. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. (June 2013). "Glucocorticoids for acute viral bronchiolitis in infants and young children". The Cochrane Database of Systematic Reviews. 2013 (6): CD004878. doi:10.1002/14651858.CD004878.pub4. PMC   6956441 . PMID   23733383.
32. Jat KR, Dsouza JM, Mathew JL (April 2022). "Continuous positive airway pressure (CPAP) for acute bronchiolitis in children". The Cochrane Database of Systematic Reviews. 2022 (4): CD010473. doi:10.1002/14651858.CD010473.pub4. PMC   8978604 . PMID   35377462.
33. Umoren R, Odey F, Meremikwu MM (January 2011). "Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age". The Cochrane Database of Systematic Reviews (1): CD006435. doi:10.1002/14651858.CD006435.pub2. PMID   21249676.
34. Kua KP, Lee SW (2017). "Complementary and alternative medicine for the treatment of bronchiolitis in infants: A systematic review". PLOS ONE. 12 (2): e0172289. Bibcode:2017PLoSO..1272289K. doi: 10.1371/journal.pone.0172289 . PMC   5315308 . PMID   28212381.
35. Chirico, G.; Beccagutti, F. (October 2010). "Nasal obstruction in neonates and infants". Minerva Pediatrica. 62 (5): 499–505. ISSN   0026-4946. PMID   20940683.
36. Schuh, Suzanne; Coates, Allan L.; Sweeney, Judy; Rumantir, Maggie; Eltorki, Mohamed; Alqurashi, Waleed; Plint, Amy C.; Zemek, Roger; Poonai, Naveen; Parkin, Patricia C.; Soares, Diane; Moineddin, Rahim; Finkelstein, Yaron; Pediatric Emergency Research Canada (PERC) Network; Carciumaru, Redjana (19 October 2023). "Nasal Suctioning Therapy Among Infants With Bronchiolitis Discharged Home From the Emergency Department: A Randomized Clinical Trial". JAMA Network Open. 6 (10): e2337810. doi:10.1001/jamanetworkopen.2023.37810. ISSN   2574-3805. PMC   10587796 . PMID   37856126.
37. Gill PJ, Anwar MR, Kornelsen E, Parkin P, Mahood Q, Mahant S (December 2021). "Parenteral versus enteral fluid therapy for children hospitalised with bronchiolitis". The Cochrane Database of Systematic Reviews. 2021 (12): CD013552. doi:10.1002/14651858.CD013552.pub2. PMC   8635777 . PMID   34852398.
38. Lin J, Zhang Y, Xiong L, Liu S, Gong C, Dai J (June 2019). "High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis". Archives of Disease in Childhood. 104 (6): 564–576. doi:10.1136/archdischild-2018-315846. PMID   30655267. S2CID   58666508.
39. Dafydd, Carwyn; Saunders, Benjamin J.; Kotecha, Sarah J.; Edwards, Martin O. (29 July 2021). "Efficacy and safety of high flow nasal oxygen for children with bronchiolitis: systematic review and meta-analysis". BMJ Open Respiratory Research. 8 (1): e000844. doi:10.1136/bmjresp-2020-000844. ISSN   2052-4439. PMC   8323377 . PMID   34326153.
40. Combret Y, Prieur G, LE Roux P, Médrinal C (June 2017). "Non-invasive ventilation improves respiratory distress in children with acute viral bronchiolitis: a systematic review". Minerva Anestesiologica. 83 (6): 624–637. doi:10.23736/S0375-9393.17.11708-6. PMID   28192893.
41. Jat KR, Mathew JL (January 2019). "Continuous positive airway pressure (CPAP) for acute bronchiolitis in children". The Cochrane Database of Systematic Reviews. 1 (1): CD010473. doi:10.1002/14651858.CD010473.pub3. PMC   6354031 . PMID   30701528.
42. Jat, Kana R; Dsouza, Jeanne M; Mathew, Joseph L (4 April 2022). Cochrane Acute Respiratory Infections Group (ed.). "Continuous positive airway pressure (CPAP) for acute bronchiolitis in children". Cochrane Database of Systematic Reviews. 2022 (4): CD010473. doi:10.1002/14651858.CD010473.pub4. PMC   8978604 . PMID   35377462.
43. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP (December 2017). "Nebulised hypertonic saline solution for acute bronchiolitis in infants". The Cochrane Database of Systematic Reviews. 2017 (12): CD006458. doi:10.1002/14651858.CD006458.pub4. PMC   6485976 . PMID   29265171.
44. Brooks CG, Harrison WN, Ralston SL (June 2016). "Association Between Hypertonic Saline and Hospital Length of Stay in Acute Viral Bronchiolitis: A Reanalysis of 2 Meta-analyses". JAMA Pediatrics. 170 (6): 577–584. doi: 10.1001/jamapediatrics.2016.0079 . PMID   27088767.
45. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C (October 2015). "Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review". Pediatrics. 136 (4): 687–701. doi: 10.1542/peds.2015-1914 . PMID   26416925.
46. Zhang L, Gunther CB, Franco OS, Klassen TP (August 2018). "Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: A meta-analysis". Pediatric Pulmonology. 53 (8): 1089–1095. doi:10.1002/ppul.24066. PMID   29893029. S2CID   48358175.
47. Gadomski AM, Scribani MB (June 2014). "Bronchodilators for bronchiolitis". The Cochrane Database of Systematic Reviews. 2014 (6): CD001266. doi:10.1002/14651858.CD001266.pub4. PMC   7055016 . PMID   24937099.
48. "Bronchiolitis - Clinical Practice Guideline". www.aafp.org. Archived from the original on 23 October 2019. Retrieved 23 October 2019.
49. Chavasse R, Seddon P, Bara A, McKean M (2002). "Short acting beta agonists for recurrent wheeze in children under 2 years of age". The Cochrane Database of Systematic Reviews. 2002 (3): CD002873. doi:10.1002/14651858.CD002873. PMC   8456461 . PMID   12137663.
50. Kellner JD, Ohlsson A, Gadomski AM, Wang EE (November 1996). "Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis". Archives of Pediatrics & Adolescent Medicine. 150 (11): 1166–1172. doi:10.1001/archpedi.1996.02170360056009. PMID   8904857. S2CID   25465924.
51. Everard, ML; Bara, A; Kurian, M; Elliott, TM; Ducharme, F; Mayowe, V (20 July 2005). "Anticholinergic drugs for wheeze in children under the age of two years". The Cochrane Database of Systematic Reviews. 2005 (3): CD001279. doi:10.1002/14651858.CD001279.pub2. PMC   7027683 . PMID   16034861.
52. Bjornson C, Russell K, Vandermeer B, Klassen TP, Johnson DW (October 2013). "Nebulized epinephrine for croup in children". The Cochrane Database of Systematic Reviews (10): CD006619. doi:10.1002/14651858.CD006619.pub3. PMID   24114291.
53. Kua KP, Lee SW (2017). "Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Epinephrine and Corticosteroid Therapy for Acute Bronchiolitis in Infants". Frontiers in Pharmacology. 8: 396. doi: 10.3389/fphar.2017.00396 . PMC   5479924 . PMID   28690542.
54. Farley R, Spurling GK, Eriksson L, Del Mar CB (October 2014). "Antibiotics for bronchiolitis in children under two years of age". The Cochrane Database of Systematic Reviews. 2014 (10): CD005189. doi:10.1002/14651858.CD005189.pub4. PMC   10580123 . PMID   25300167.
55. McCallum GB, Plumb EJ, Morris PS, Chang AB (August 2017). "Antibiotics for persistent cough or wheeze following acute bronchiolitis in children". The Cochrane Database of Systematic Reviews. 2017 (8): CD009834. doi:10.1002/14651858.CD009834.pub3. PMC   6483479 . PMID   28828759.
56. Che SY, He H, Deng Y, Liu EM (August 2019). "[Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis]". Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics. 21 (8): 812–819. doi:10.7499/j.issn.1008-8830.2019.08.014. PMC   7389899 . PMID   31416508.
57. Alarcón-Andrade G, Cifuentes L (May 2018). "Should systemic corticosteroids be used for bronchiolitis?". Medwave. 18 (3): e7207. doi: 10.5867/medwave.2018.03.7206 . PMID   29750779.
58. Alarcón-Andrade G, Cifuentes L (April 2018). "Do inhaled corticosteroids have a role for bronchiolitis?". Medwave. 18 (2): e7183. doi: 10.5867/medwave.2018.02.7182 . PMID   29677180.
59. Fernandes RM, Wingert A, Vandermeer B, Featherstone R, Ali S, Plint AC, et al. (August 2019). "Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis". BMJ Open. 9 (8): e028511. doi:10.1136/bmjopen-2018-028511. PMC   6688746 . PMID   31375615.
60. Pérez-Gutiérrez F, Otárola-Escobar I, Arenas D (December 2016). "Are leukotriene inhibitors useful for bronchiolitis?". Medwave. 16 (Suppl5): e6799. doi: 10.5867/medwave.2016.6799 . PMID   28032855.
61. Peng WS, Chen X, Yang XY, Liu EM (March 2014). "Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing". Pediatric Allergy and Immunology. 25 (2): 143–150. doi:10.1111/pai.12124. PMID   24118637. S2CID   27539127.
62. Liu F, Ouyang J, Sharma AN, Liu S, Yang B, Xiong W, Xu R (March 2015). "Leukotriene inhibitors for bronchiolitis in infants and young children". The Cochrane Database of Systematic Reviews. 2015 (3): CD010636. doi:10.1002/14651858.CD010636.pub2. PMC   10879915 . PMID   25773054.
63. Sanders, Sharon L.; Agwan, Sushil; Hassan, Mohamed; Bont, Louis J.; Venekamp, Roderick P. (23 October 2023). "Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection". The Cochrane Database of Systematic Reviews. 2023 (10): CD009417. doi:10.1002/14651858.CD009417.pub3. ISSN   1469-493X. PMC   10591280 . PMID   37870128.
64. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, et al. (April 2011). "Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis". BMJ. 342: d1714. doi:10.1136/bmj.d1714. PMC   3071611 . PMID   21471175.
65. Jat KR, Chawla D (August 2015). "Surfactant therapy for bronchiolitis in critically ill infants". The Cochrane Database of Systematic Reviews. 2015 (8): CD009194. doi:10.1002/14651858.CD009194.pub3. PMC   7104667 . PMID   26299681.
66. Lauwers E, Ides K, Van Hoorenbeeck K, Verhulst S (November 2018). "The effect of intrapulmonary percussive ventilation in pediatric patients: A systematic review". Pediatric Pulmonology. 53 (11): 1463–1474. doi:10.1002/ppul.24135. hdl: 10067/1522720151162165141 . PMID   30019451. S2CID   51680313.
67. Roqué-Figuls, Marta; Giné-Garriga, Maria; Granados Rugeles, Claudia; Perrotta, Carla; Vilaró, Jordi (3 April 2023). Cochrane Acute Respiratory Infections Group (ed.). "Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old". Cochrane Database of Systematic Reviews. 2023 (4): CD004873. doi:10.1002/14651858.CD004873.pub6. PMC   10070603 . PMID   37010196.
68. Kuitunen, Ilari; Kiviranta, Panu; Sankilampi, Ulla; Salmi, Heli; Renko, Marjo (June 2022). "Helium–oxygen in bronchiolitis—A systematic review and meta-analysis". Pediatric Pulmonology. 57 (6): 1380–1391. doi:10.1002/ppul.25895. ISSN   8755-6863. PMC   9313870 . PMID   35297227.
69. Enriquez A, Chu IW, Mellis C, Lin WY (November 2012). "Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months". The Cochrane Database of Systematic Reviews. 11 (11): CD008395. doi:10.1002/14651858.CD008395.pub2. PMC   7388903 . PMID   23152257.
70. Kua KP, Lee SW (17 February 2017). "Complementary and alternative medicine for the treatment of bronchiolitis in infants: A systematic review". PLOS ONE. 12 (2): e0172289. Bibcode:2017PLoSO..1272289K. doi: 10.1371/journal.pone.0172289 . PMC   5315308 . PMID   28212381.
71. Heemskerk, Susanne; van Heuvel, Lotte; Asey, Tamana; Bangert, Mathieu; Kramer, Rolf; Paget, John; van Summeren, Jojanneke (August 2024). "Disease Burden of RSV Infections and Bronchiolitis in Young Children (< 5 Years) in Primary Care and Emergency Departments: A Systematic Literature Review". Influenza and Other Respiratory Viruses. 18 (8): e13344. doi:10.1111/irv.13344. ISSN   1750-2640. PMC   11298312 . PMID   39098881.

External links

• Bronchiolitis. Patient information from NHS Choices
• "Bronchiolitis in children – A national clinical guideline" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 6 December 2007. (1.74 MB) from the Scottish Intercollegiate Guidelines Network
• Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. (November 2014). "Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis". Pediatrics. 134 (5): e1474–e1502. doi: 10.1542/peds.2014-2742 . PMID   25349312.